The pathobiology of endothelin-1 in vein graft disease: Are ETA receptor antagonists the solution to prevent vein graft failure?

Current Vascular Pharmacology

Volumn 3, Issue 4, 2005, Pages 315-323

  Jeremy, Jamie Y ^a   Shukla, Nilima ^a   Wan, Song ^b   Murphy, Gavin ^a   Angelini, Gianni D ^a   Yim, Anthony ^b   Dashwood, Michael R ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bypass surgery; Endothelin; Endothelin receptors; Occlusion; Vein graft

Indexed keywords

ANTILIPEMIC AGENT; CELL ADHESION MOLECULE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; GROWTH FACTOR; METALLOPROTEINASE; NITRIC OXIDE; PEPTIDE DERIVATIVE; PROSTACYCLIN; SCLEROPROTEIN;

ATHEROGENESIS; BYPASS SURGERY; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EVIDENCE BASED MEDICINE; FLOW KINETICS; GRAFT FAILURE; HEMODYNAMICS; HUMAN; HYPOXIA; INTIMA; LEG BLOOD VESSEL; LEUKOCYTE; LIVER DYSFUNCTION; MICROVASCULATURE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; SURGICAL INJURY; THROMBOCYTE ADHESION; VASA VASORUM; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASCULAR SURGERY; VEIN GRAFT DISEASE;

EID: 24644459881     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016105774329499     Document Type: Review

References (170)

1. Favaloro R. Critical analysis of coronary artery bypass graft surgery: a 30 year journey. JACC 1998; 31: 1B-63B.
2. Mortwani JG, Topol EJ. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation 1998; 97: 916-931.
3. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1999; 28: 616-626.
4. Jackson MR, Belott TP, Dickason T, Kaiser WJ, Modrall JG, Valentine RJ, et al. The consequences of a failed femoropopliteal bypass grafting: comparison of a saphenous vein and PTFE graft. J Vasc Surg 2000; 32: 498-505.
5. Davies MG, Hagen P-O. Pathobiology of intimal hyperplasia. Br J Surg 1995; 81: 1254-1269.
6. Watanabe T, Pakala R, Katagiri T, Benedict CR. Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. J Hypertens 2001; 19: 731-739.
7. Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 1999; 96: 1633-1638.
8. Rizvi MA, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol 1997; 29: 1779-1789.
9. Hafizi S, Allen SP, Goodwin AT, Chester AH, Yacoub MH. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis 1999; 146: 351-359.
10. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999; 100: 5-8
11. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical -generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 1999; 56: 471-478.
12. Davenport AP, Maguire JJ. The endothelin system in human saphenous vein graft disease. Curr Opin Pharmacol 2001; 1: 176-182.
13. Trachtenberg JD, Sun S, Choi ET, Callow AD, Ryan US. Effect of endothelin infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol 1993; S355-359.
14. Douglas SA, Vickery-Clark LM, Storer BL, Harty T, Louden C, Elliott JD, et al. A role for endogenous endothelin-1 in neointima formation following rat carotid artery balloon angioplasty: antiproliferative effects of the non-peptide endothelin receptor antagonist, SB 209670. Circ Res 1994; 75: 190-197.
15. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller NL, Durham SK, et al. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon injured rat carotid arteries. J Cardiovasc Pharmacol 1995; 26: 908-915.
16. Porter KE, Dickinson T, London NJ. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition. J Vasc Surg 2001; 34: 548-554.
17. Maguire JJ, Davenport AP. Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol 1999; 126: 443-450.
18. Maguire JJ, Davenport AP. ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci 2002; 103: 1845-1885.
19. A receptor antagonist, BSF 302146, is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Cardiovasc Surg 2004: 127: 1317-1322.
20. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphological study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986; 6: 594-600.
21. Schwartz SM, deBlois D, O'Brien ERM. The neointima: soil for atherosclerosis and restenosis. Circ Res 1996; 77: 445-465.
22. Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol 2000; 15: 395-399.
23. Jeremy JY, Bryan AJ, Angelini GD. Pathophysiology and treatment of vein graft failure. J Drug Develop 1996; 7: 309-313.
24. Jeremy JY, Jackson CL, Bryan AJ. Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Prostagl Leukotr Essential Fatty Acids 1996; 54: 385-402.
25. Thatte HS, Khuri SF. The coronary artery bypass conduit: Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg 2001; 72: S2245-S2252.
26. Dobrin PB, Golan J, Fareed J. Pre- vs postoperative pharmacologic inhibition of platelets: effect on intimal hyperplasia in canine autogenous vein grafts. J Cardiovasc Surg 1992; 33: 705-709.
27. Lerner RG, Moggio RA, Reed GE. Endothelial loss due to leukocytes in canine experimental vein-to-artery grafts. Blood Vessels 1986; 23: 173-182.
28. Cooper JP, Newby AC. Monocyte adhesion to human saphenous vein in vitro. Atherosclerosis 1991; 91: 85-95.
29. Eslami MH, Gangadharan SP, Belkin M, Donaldson MC, Whittemore AD, Conte MS. Monocyte adhesion to human vein grafts: a marker for occult intraoperative injury? J Vasc Surg 2001; 34: 923-929.
30. Hernandez R, Alemany M, Bozzo J, Buchanan MR, Ordinas A, Bastida E. Platelet adhesivity to subendothelium is influenced by polymorphonuclear leukocytes: studies with aspirin and salicylate. Haemostasis 1993; 23: 1-7.
31. Jeremy JY, Mehta D, Bryan AJ, Angelini GD. Platelets and saphenous vein graft failure. Platelets 1997; 8: 295-309.
32. Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, et al. Activated platelets and leucocytes co-operatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc Res 1999; 43: 210-218.
33. Golino P, Ambrosio G, Ragni M, Cirillo P, Esposito N, Willerson JT, et al. Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 1997; 77: 783-788.
34. Schwarcz TH, Dobrin PB. Role of platelets in the formation of intimal hyperplasia. Circ Res 1995; 77: 445-463.
35. Bienvenu JG, Tanguay JF, Chauvet P, Merhi Y. Relationship between platelets and neutrophil adhesion and neointimal growth after repeated arterial wall injury induced by angioplasty in pigs. J Vasc Res 2001; 38: 153-162.
36. Miller AM, McPhaden AR, Wadsworth RM. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res 2001; 49: 838-850.
37. Hoch JR, Stark VK, Hullett DA. Vein graft intimal hyperplasia: leukocytes and cytokine gene expression. Surgery 1994;116: 463-470.
38. Hoch JR, Stark VK, Turnipseed WD. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J Vasc Surg 1995; 22: 51-58.
39. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun. 1991; 174: 613-8
40. Gomez-Garre D, Guerra M, Gonzalez E, Lopez-Farre A, Riesco A, Caramelo C, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol. 1992; 224: 167-172.
41. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
42. Chen A, Zhong N. Zafirlukast inhibition of leukotriene C4 induced endothelin-1 expression in human airway structural cell. Zhonghua Jie He He Hu Xi Za Zhi 2000; 23: 617-620.
43. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999; 56: 471-478.
44. Golden CG, Nick HS, Visner GA. Thrombin regulation of endothelin-1 gene in isolated human pulmonary endothelial cells. Chest 1998; 114: 63S-64S.
45. Lepailleur-Enouf D, Valdenaire O, Philippe M, Jandrot-Perrus M, Michel JB. Thrombin induces endothelin expression in arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1606-12.
46. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004; 61: 159-68.
47. Naito S, Shimizu S, Maeda S, Wang J, Paul R, Fagin JA. Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol 1998; 274: C472-C480.
48. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol. 1999; 55: 902-9.
49. Kwok CF, Juan CC, Shih KC, Hwu CM, Jap TS, Ho LT. Insulin-like growth factor-1 increases endothelin receptor A levels and action in cultured rat aortic smooth muscle cells. J Cell Biochem. 2005; 94: 1126-1134.
50. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol. 1992; 262: C854-C861.
51. Dashwood MR, Barker SG, Muddle JR, Yacoub MH, Martin JF. [125I]-endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimal hyperplasia and atherosclerosis. J Cardiovasc Pharmacol. 1993; 22 Suppl 8: S343-7.
52. Dashwood MR, Mehta D, Izzat MB, Timm M, Bryan AJ, Angelini GD, et al. Distribution of endothelin-1 (ET) receptors [ET(A) and ET(B) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts, Atherosclerosis 1998; 137: 233-242.
53. Dashwood MR, Jeremy JY, Mehta D, Izzat MB, Timm M, Bryan AJ, et al. Endothelin-1 and endothelin receptors in porcine saphenous vein-carotid artery grafts. J Cardiovasc Pharmacol 1998; 31 Suppl 1: S328-S330.
54. Gryglewski RJ, Chlopicki, Swies J. Prostacyclin, nitric oxide and atherosclerosis. Ann NY Acad Sci USA 1995; 748: 194-207.
55. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315-331.
56. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res 1999; 43: 658-665.
57. Jeremy JY, Birkett S, Bryan AJ, Angelini GD. Cyclic nucleotide synthesis by freshly isolated and surgically prepared human saphenous vein before and after 14 days culture. Eur J Vasc Endovasc Surg 1997; 13: 72-78.
58. Jeremy JY, Shukla N, Muzaffar S, Angelin GD. Reactive oxygen species, vascular disease and cardiovascular surgery. Current Vascular Pharmacology 2004; 2: 229-236.
59. Jeremy JY, Yim AP, Wan S, Angelini GD. Oxidative stress, nitric oxide and vascular disease. Cardiovascular Surgery 2002; 17: 324-327.
60. Jeremy JY, Dashwood M, Timm M, Izzat M, Angelini G. Nitric oxide synthase and cyclic nucleotide synthesis by porcine venous-arterial grafts. Ann Thorac Surg 1997; 63: 470-476.
61. Jeremy JY, Dashwood M, Mehta D, Izzat MB, Bryan AJ, Angelini GD. Nitric oxide synthase, prostacyclin and cyclic nucleotide production in externally stented porcine vein grafts. Atherosclerosis 1998; 141: 297-305.
62. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1994; 269: 11938-11944.
63. Wort SJ, Mitchell JA, Woods M, Evans TW, Warner TD. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. J Cardiovasc Pharmacol 2000; 36: S410-S413.
64. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Matsumura Y. Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. Clin Sci (Lond) 2002; 103: 68S-71S.
65. Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ. Endotheliall healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 2002; 105: 1686-1692.
66. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 1991; 83: 402-411.
67. Davies MG, Klyachkin ML, Svendsen E, Hagen PO. A comparative study of endothelium-derived relaxing factor-mediated relaxation and smooth muscle cell function in arterial and venous vein bypass grafts. Cardiovasc Surg 1996a; 4: 150-160.
68. Shimokawa H, Aarhus LL, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987; 61: 256-70.
69. Powell JT, Gosling M. Molecular and cellular changes in vein grafts: influence of pulsatile stretch. Curr Opin Cardiol 1998; 13: 453-458.
70. Ohno N, Itoh H, Ikeda T, Ueyama K, Yamahara K, Doi K, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-1626.
71. Smith PJ, Teichert-Kuliszewska K, Monge JC, Stewart DJ. Regulation of endothelin-B receptor mRNA expression in human endothelial cells by cytokines and growth factors. J Cardiovasc Pharmacol 1998; 31 Suppl 1: S158-60.
72. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol. 1999; 26: 269-271.
73. Aplin AE, Howe A, Alahari SK, Dietrich H, Wick G, Xu Q. et al. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-263.
74. Stark VK, Hoch JR, Warner TF. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997a; 17: 1614-1621.
75. Zou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q. Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 2000; 86: 434-440.
76. Crook MF, Newby AC, Southgate KM. Expression of intercellular adhesion molecules in human saphenous veins: effects of inflammatory cytokines and neointima formation in culture. Atherosclerosis 2000; 150: 33-41.
77. Chester AH, Morrison KJ, Yacoub MH. Expression of vascular adhesion molecules in saphenous vein coronary artery bypass grafts. Ann Thorac Surg 1998; 65: 1685-1689.
78. Alrawi SJ, Samee M, Raju R, Shirazian D, Acinapura AJ, Cunningham JN. Intercellular and vascular cell adhesion molecule levels in endoscopic and open saphenous vein harvesting for coronary artery bypass graft surgery. Heart Surg Forum 2000; 3: 241-245.
79. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb Vasc Biol 1995; 15: 2-10.
80. Walpola PL, Gotlieb AI, Langille BL. Monocyte adhesion and changes in endothelial cell number, morphology, and F-actin distribution elicited by low shear stress in vivo. Am J Pathol 1993; 142: 1392-1400.
81. Sato Y, Hogg JC, English D, van Eeden SF. Endothelin-1 changes polymorphonuclear leukocytes' deformability and CD11b expression and promotes their retention in the lung. Am J Respir Cell Mol Biol 2000; 23: 404-410.
82. Elferink JG, de Koster BM. Endothelin-induced activation of neutrophil migration. Biochem Pharmacol 1994; 48: 865-871.
83. Boros M, Massberg S, Baranyi L, Okada H, Messmer K. Endothelin 1 induces leukocyte adhesion in submucosal venules of the rat small intestine. Gastroenterology 1998; 114: 103-114.
84. Zouki C, Baron C, Fournier A, Filep JG. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol 1999; 127: 969-79.
85. Cambiaggi C, Mencarelli M, Muscettola M, Grasso G. Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils. Cytokine 2001 21; 14: 230-233.
86. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1. FASEB J 2001; 15: 2230-2240.
87. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension. 2003; 42: 997-1003.
88. Sanz MJ, Johnston B, Issekutz A, Kubes P. Endothelin-1 causes P-selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels. Am J Physiol 1999; 277: H1823-30.
89. Zouki C, Baron C, Fournier A, Filep JG. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol. 1999; 127: 969-79.
90. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol. 1999; 369: 237-245.
91. Plusczyk T, Witzel B, Menger MD, Schilling M. ETA and ETB receptor function in pancreatitis-associated microcirculatory failure, inflammation, and parenchymal injury. Am J Physiol Gastrointest Liver Physiol 2003; 285: G145-G153.
92. Bajory Z, Hutter J, Krombach F, Messmer K. The role of endothelin-1 in ischemia-reperfusion induced acute inflammation of the bladder in rats. J Urol 2002; 168: 1222-1225.
93. Plusczyk T, Bersal B, Menger MD, Feifel G. Differential effects of ET-1, ET-2, and ET-3 on pancreatic microcirculation, tissue integrity, and inflammation. Dig Dis Sci 2001; 46: 1343-1351.
94. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. Eur J Pharmacol 2000; 407: 1-15.
95. Van der Wal AC, Becker AE, Elbers JR. An immunocytochemical analysis of rapidly progressive atherosclerosis in human vein grafts. Eur J Cardiothorac Surg 1992; 6: 469-473.
96. Hoch JR, Stark VK, van Rooijen N. Macrophage depletion alters vein graft intimal hyperplasia. Surgery 1999; 126: 428-437.
97. Yamaguchi A, Miniati DN, Hirata K, Hoyt EG, Robbins RC. Ex vivo blockade of endothelin-1 inhibits graft coronary artery disease in a rodent cardiac allograft model. J Heart Lung Transplant. 2002; 21: 417-424.
98. Haug C, Schmid-Kotsas A, Zorn U, Schuett S, Gross HJ, Gruenert A, et al. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. J Mol Cell Cardiol 2001; 33: 1701-1712.
99. Wilson SH, Simari RD, Lerman A. The effect of endothelin-1 on nuclear factor kappa B in macrophages. Biochem Biophys Res Commun. 2001; 286: 968-972.
100. Aliev G, Smith MA, Turmaine M, Neal ML, Zimina TV, Friedland RP, et al. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Exp Mol Pathol 2001; 71: 40-54.
101. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002; 160: 297-304.
102. Gray GA, Battistini B, Webb DJ. Endothelins are potent vasoconstrictors, and much more besides. Trends Pharmacol Sci 2000; 21: 38-40.
103. Kowala MC, Rose PM, Stein PD, Goller N, Reece R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995; 146: 819-826.
104. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.
105. Langenfeld MR, Nakhla S, Death AK, Jessup W, Celermajer DS. Endothelin-1 plus oxidized low-density lipoprotein, but neither alone, increase human monocyte adhesion to endothelial cells. Clin Sci (Lond) 2001; 101: 731-738.
106. Dobrin PB, Littoy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery 1989; 105: 393-400.
107. Gibbons GH, Dzau V. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
108. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Revs 2001; 81: 999-1030.
109. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525-1541.
110. Kawano K, Yoshino H, Aoki N, Udagawa H, Watanuki A, Hioki Y. Shear-induced platelet aggregation increases in patients with proximal and severe coronary artery stenosis. Clin Cardiol 2002; 25: 154-160.
111. Turitto VT, Hall CL. Mechanical factors affecting hemostasis and thrombosis. Thromb Res 1998; 92: S25-S31.
112. Caro C, Jeremy JY, Watkins N, Bulbulia R, Angelini GD, Smith FC, et al. Geometry of unstented and stented pig common carotid artery bypass grafts. J Biorheol 2002; 39: 507-512.
113. Wang DL, Wung BS, Peng YC, Wang JJ. Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells. J Cell Physiol 1995; 163: 400-406.
114. Hosokawa H, Aiuchi S, Kambe T, Hagiwara Y, Kubo T. Mechanical stretch-induced mitogen-activated protein kinase activation is mediated via angiotensin and endothelin systems in vascular smooth muscle cells. Biol Pharm Bull 2002; 25: 1588-1592.
115. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol. 2003; 285: H2225-H2232.
116. Resnick N, Gimbrone MA Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J 1995; 9: 874-882.
117. Osol G. Mechanotransduction by vascular smooth muscle. J Vasc Res 1995; 32: 275-292.
118. Dashwood M, Anand R, Loesch A, Souza D. Surgical trauma and vein graft failure: further evidence for a role of ET-1 in graft occlusion. J Cardiovasc Pharmacol 2004;44(suppl 1):S16-19.
119. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
120. Sihvola RK, Pulkkinen VP, Koskinen PK, Lemstrom KB. Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. J Am Coll Cardiol 2002; 39: 710-717.
121. Hafizi S, Wharton J, Chester AH, Yacoub MH. Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem 2004; 14: 285-292.
122. Morgera S, Schlenstedt J, Hambach P, Giessing M, Deger S, Hocher B, et al. Combined ETA/ETB receptor blockade of human peritoneal mesothelial cells inhibits collagen 1 RNA synthesis. Kidney Int. 2003; 64: 2033-2040.
123. Schwarz A, Godes M, Thone-Reineke C, Theuring F, Bauer C, Neumayer HH, et al. Tissue-dependent expression of matrix proteins in human endothelin-1 transgenic mice. Clin Sci (Lond). 2002; 103: 39S-43S.
124. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol. 2001; 116: 417-425.
125. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1. FASEB J 2001; 15: 2230-2240.
126. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. Lab Clin Med. 1998; 132: 9-15.
127. Gadsdon P, Yim A, Wan S, Johnson JL, Angelini GD. Nitrated tyrosine in porcine stented and unstented vein grafts. Atherosclerosis 2000; 151: 108, TuP3.
128. Muzaffar S, Jeremy JY, Angelini GD, Stuart-Smith K, Shukla N. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 2003; 58: 598-604
129. 2a in cultured porcine pulmonary artery vascular smooth muscle cells. Br J Pharmacol 2004; 141: 488-496.
130. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Nitroaspirins and SlN-1, but not aspirin, inhibit the expression of endotoxin- and cytokine- induced NAPDH oxidase in vascular smooth muscle cells from pig pulmonary arteries. Circulation 2004: 110: 1140-1147.
131. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ET(B) receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005.
132. Touyz RM, Yao G, Viel E, Amiri F, Schiffirin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22: 1141-9.
133. Liu JC, Chen JJ, Chan P, Cheng CF, Cheng TH. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003; 42: 1198-11205.
134. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-8.
135. George SJ, Izzat MB, Gadsdon P, Johnson JL, Yim AP, Wan S, et al. Macro-porosity is necessary for the reduction of neointimal and medial thickening by external stenting of porcine saphenous vein bypass grafts. Atherosclerosis. 2001; 155: 329-36.
136. Vijayan V, Smith FC, Angelini GD, Bulbulia RA, Jeremy JY. External supports and the prevention of neointima formation in vein grafts. Eur J Vasc Endovasc Surg 2002; 24: 13-22.
137. Jeremy JY, Bulbulia R, Vijayan V, Johnson JL, Gadsdon P, Angelini GD. A bioabsorbable (polyglactin) external sheath inhibits porcine saphenous vein graft thickening. J Thorac Cardiovasc Surg 2004: 127: 1766-1772.
138. Vijayan V, Shukla N, Smith FCT, Angelini GD, Jeremy JY. A polyglactin biodegradable external stent prevents medial and intimal thickening but promotes marked neo vasa vasorum formation in porcine saphenous vein grafts in both the short and long term. J Vasc Surg 2004 40: 1011-1019.
139. Dashwood MR, Anand R, Loesch A, Souza DS. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology 2004; 55: 385-395.
140. Barker SG, Talbert A, Cottam S, Baskerville PA, Martin JF. Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thrombos 1993; 13: 70-77.
141. Martin JF, Booth RFG, Moncada S. Arterial wall hypoxia following thrombosis of the vasa vasorum is an initial lesion in atherosclerosis. Eur J Clin Invest 1991; 21: 355-359.
142. Batson RC, Sottiurai VS. Non-reversed and in situ vein grafts: clinical and experimental observations. Ann Surg 1985; 201: 770-779.
143. McGeachie JK, Campbell PA, Predergast FJ. Vein to artery grafts: a quantitative study of revascularisation by vasa vasorum and its relationship to intimal hyperplasia. Ann Surg 1981; 194: 100-107.
144. x and endothelial nitric oxide synthase in the pulmonary artery. Thorax 2005; 60: 305-313.
145. Kourembanas S, Marsedn PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88: 1054-1057.
146. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26: 74-84.
147. Tsui JC, Baker DM, Biecker E, Shaw S, Dashwood MR. Altered endothelin-1 levels in acute lower limb ischemia and reperfusion. Angiology 2004; 55: 533-539.
148. Khimenko PL, Moore TM, Taylor AE. Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. J Appl Physiol. 1996; 80: 203-207.
149. Izzat MB, Mehta D, Bryan AJ, Reeves B, Newby AC, Angelini GD. The influence of external stent size on early medial and neointimal thickening in a pig model of saphenous vein bypass grafting. Circulation 1996; 94: 1741-1745.
150. Mehta D, George SJ, Jeremy JY, Izzat MB, Southgate KM, Bryan AJ, et al. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nature Med 1998; 4: 235-239.
151. Jeremy JY, Dashwood MR. Microvascular Repair. In: Encyclopaedia of the microvasculature. 2005: in press.
152. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14: 44-50.
153. Bek EL, McMillen MA, Scott P, Angus LD, Shaftan GW. The effect of diabetes on endothelin, interleukin-8 and vascular endothelial growth factor-mediated angiogenesis in rats. Clin Sci (Lond) 2002; 103 suppl 48: 424S-429S.
154. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002; 277: 27850-27855.
155. Bek EL, McMillen MA. Endothelins are angiogenic. J Cardiovasc Pharmacol 2000; 36: S135-S139.
156. Muller L, Valdenaire O, Barret A, Korth P, Pinet F, Corvol P, et al. Expression of the endothelin-converting enzyme-1 isoforms in endothelial cells. J Cardiovasc Pharmacol 2000; 36: S15-S18.
157. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999; 26: 269-271.
158. Lahav R, Suva ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 2004; 64: 8945-8953.
159. Wulfing P, Kersting C, Tio J, Fischer RJ, Wulfing C, Poremba C, et al. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004; 10: 2393-2400.
160. Tsui JC, Souza DS, Filbey D, Bomfim V, Dashwood MR. Preserved endothelial integrity and nitric oxide synthase in saphenous vein grafts harvested by a 'no-touch' technique. Br J Surg 2001; 88: 1209-1215.
161. Tsui JC, Souza DS, Filbey D, Karlsson MG, Dashwood MR. Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel "no-touch" technique: potential role of nitric oxide contribution to improved early graft patency rates. J Vasc Surg 2002; 35: 356-362.
162. Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, et al. Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. Ann Thorac Surg 2002; 73: 1189-1195.
163. Wackenfors A, Ingemansson R, Malmsjo M. Endothelin receptors in endothelium-denuded human coronary artery bypass grafts and coronary arteries. Ann Thorac Surg 2003; 75: 874-881.
164. A receptor antagonism improves coronary compliance in coronary artery disease patients. Clin Science 2002; 103 (suppl 48):179S-183S.
165. A receptor blockade improves post-ischaemic functional recovery in
166. Duru F, Barton M, Luscher F, Candinas R. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res 2001; 272-80.
167. Brooks DP, dePalma PD, Gellai M, Nambi P, Ohlstein EH, Elliott JD, et al. Nonpeptide endothelin receptor antagonists. III. Effect of SB209670 and BQ123 on acute renal failure in anaesthetised dogs. J Pharmacol Exp Ther 1994; 271: 1-7.
168. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43: 62S-67S.
169. Doggrell SA, Brown L. Present and future pharmacotherapy for heart failure. Expert Opin Pharmacother. 2002; 3: 915-30.
170. Nelson JB. Endothelin receptor antagonists. World J Urol. 2005; 23: 19-27.